Continuous Infusion of Recombinant Factor VIIa (NovoSeven®) in the Treatment of a Patient with Type III von Willebrand’s Disease and Alloantibodies against von Willebrand Factor

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2000-04, Vol.83 (4), p.633-634
Hauptverfasser:	Grossmann, R.E., Geisen, U., Schwender, S., Keller, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaphylaxis - etiology Epistaxis - etiology Epistaxis - therapy Factor VIIa - administration & dosage Factor VIIa - therapeutic use Hematoma - etiology Hematoma - therapy Humans Infusions, Intravenous Isoantibodies - immunology Letters to the Editor Male Middle Aged Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - therapeutic use Recurrence von Willebrand Diseases - classification von Willebrand Diseases - complications von Willebrand Diseases - immunology von Willebrand Diseases - therapy von Willebrand Factor - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!